Showing results (641-650 of 735) with videos related to
Sort By:
Pageof 74
The Journal of Infection|August 23, 2025
Third exposure to COVID-19 infection or vaccination differentially impacts T cell responsesGift Ahimbisibwe, David Greenwood, Katalin Andrea Wilkinson, et al.Nature Communications|September 11, 2020
MCL-1 gains occur with high frequency in lung adenocarcinoma and can be targeted therapeuticallyEnkhtsetseg Munkhbaatar, Michelle Dietzen, Deepti Agrawal, et al.Cancer Discovery|September 8, 2025
Extrachromosomal DNA-Driven Oncogene Spatial Heterogeneity and Evolution in GlioblastomaImran Noorani, Magnus Haughey, Jens Luebeck, et al.European Journal of Cancer (Oxford, England : 1990)|May 27, 2017
Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group studyEmeline Colomba, Gwénaël Le Teuff, Tim Eisen, et al.The New England Journal of Medicine|June 7, 2011
Improved survival with vemurafenib in melanoma with BRAF V600E mutationPaul B Chapman, Axel Hauschild, Caroline Robert, et al.The New England Journal of Medicine|February 20, 2019
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell CarcinomaRobert J Motzer, Konstantin Penkov, John Haanen, et al.The New England Journal of Medicine|September 26, 2015
Nivolumab versus Everolimus in Advanced Renal-Cell CarcinomaRobert J Motzer, Bernard Escudier, David F McDermott, et al.Contemporary Clinical Trials Communications|November 18, 2024
Adapting the design of the ongoing RAMPART trial in response to external evidence: An example for trials which take many years to run and reportAngela Meade, Elena Frangou, Babak Choodari-Oskooei, et al.Journal for Immunotherapy of Cancer|August 28, 2021
Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survivalMario Mandala, James Larkin, Paolo Antonio Ascierto, et al.The Lancet. Oncology|February 11, 2014
Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label studyGrant A McArthur, Paul B Chapman, Caroline Robert, et al.Pageof 74